The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
Young biotech companies generally have restricted financial resources at the early stage and look to secure funding rounds by venture capital. Funding has become increasingly difficult to secure and expensive for biotechnology companies.
Some of the Institut Pasteur spin-offs currently welcome funds from business angels, venture capital or corporate venture funds.
Created in 2010, Axenis is a company providing preclinical research services. After more than 15 years of research and development at the Institut Pasteur, Erwan Corcuff, the CEO, offers its know-how and unique models for the realization of industrial preclinical studies.
Pierre Langlade-Demoyen, the CEO, created Invectys, a company developing vaccines against cancer, in 2010. The company's main product is a vaccine targeting telomerase protein that is involved in the immortalization of cancer cells.
Created in 2010, Pathoquest SAS is a distinctive new generation Molecular Diagnostics company that offers a game changing approach using the combination of disruptive NGS (Next Generation Sequencing) and Bioinformatics / Database tools. Luc Boblet is the CEO
Created in 2005, THERAVECTYS is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Research and development activities are based on 15 years of research conducted at the Pasteur Molecular Virology and Vectorology laboratories. Renault Vaillant is the CEO.